Nicotinamide mononucleotide administration prevents experimental diabetes-induced cognitive impairment and loss of hippocampal neurons
JournalInternational Journal of Molecular Sciences
MetadataShow full item record
AbstractDiabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD+ levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD+) levels to prevent dementia. We tested if the administration of the precursor of NAD+, nicotinamide mononucleotide (NMN), can prevent diabetes-induced memory deficits. Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ). After 3 months of diabetes, hippocampal NAD+ levels were decreased (p = 0.011). In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p < 0.001), glutamate (p < 0.001), gamma aminobutyric acid (p = 0.018), myo-inositol (p = 0.018), and taurine (p < 0.001) and decreased levels of N-acetyl aspartate (p = 0.002) and glutathione (p < 0.001). There was a significant decrease in hippocampal CA1 neuronal volume (p < 0.001) and neuronal number (p < 0.001) in the Diabetic rats. Diabetic rats showed hippocampal related memory deficits. Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months. NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione. NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control. In hippocampal protein extracts from Diabetic rats, SIRT1 and PGC-1α protein levels were decreased, and acetylation of proteins increased. NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins. Our results indicate that NMN increased brain NAD+, activated the SIRT1 pathway, preserved mitochondrial oxidative phosphorylation (OXPHOS) function, prevented neuronal loss, and preserved cognition in Diabetic rats
SponsorsVA BX004895; P30 DK072488; U.S. Department of Veterans Affairs, VA; Diabetes Action Research and Education Foundation; National Institutes of Health, NIH 1R01DK107007-01A1; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK; Institute for Clinical and Translational Research, University of Wisconsin, Madison, UW ICTR; Rehabilitation Research and Development Service, RR&D 101RX001030
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85085634691&doi=10.3390%2fijms21113756&partnerID=40&md5=8037d4665368e6a0000aec4817772a2b; http://hdl.handle.net/10713/12982
- Nicotinamide mononucleotide protects against β-amyloid oligomer-induced cognitive impairment and neuronal death.
- Authors: Wang X, Hu X, Yang Y, Takata T, Sakurai T
- Issue date: 2016 Jul 15
- Role of mitochondria in diabetic peripheral neuropathy: Influencing the NAD<sup>+</sup>-dependent SIRT1-PGC-1α-TFAM pathway.
- Authors: Chandrasekaran K, Anjaneyulu M, Choi J, Kumar P, Salimian M, Ho CY, Russell JW
- Issue date: 2019
- Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia.
- Authors: Park JH, Long A, Owens K, Kristian T
- Issue date: 2016 Nov
- Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation.
- Authors: Fang WJ, Wang CJ, He Y, Zhou YL, Peng XD, Liu SK
- Issue date: 2018 Jan
- Nicotinamide mononucleotide alters mitochondrial dynamics by SIRT3-dependent mechanism in male mice.
- Authors: Klimova N, Long A, Kristian T
- Issue date: 2019 Aug